Ratings by Cantor Fitzgerald (Steve Seedhouse)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/29/2026 | Aligos Therapeutics Inc. | ALGS | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/21/2026 | Aligos Therapeutics Inc. | ALGS | New Coverage | Overweight (N/A) |
5.60 (5.53) |
-1.25% | Details | |
| 5/19/2026 | WAVE Life Sciences | WVE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2026 | Harrow Health | HROW | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2026 | AbCellera Biologics | ABCL | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/8/2026 | NewAmsterdam Pharma Co NV | NAMS | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/7/2026 | Inova Technology, Inc. | INVA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/5/2026 | AbCellera Biologics | ABCL | New Coverage | Overweight (N/A) |
4.59 (6.07) |
32.24% | Details | |
| 4/8/2026 | Inova Technology, Inc. | INVA | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/7/2026 | Equillium | EQ | New Coverage | Overweight (N/A) |
2.01 (2.88) |
43.28% | Details | |
| 4/1/2026 | Tvardi Therapeutics Inc | TVRD | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/30/2026 | Opus Genetics | IRD | New Coverage | Overweight (N/A) |
4.35 (3.86) |
-11.26% | Details | |
| 3/24/2026 | Surrozen Inc. | SRZN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/18/2026 | Harrow Health | HROW | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/6/2026 | CAMP4 Therapeutics Corp | CAMP | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/4/2026 | Harrow Health | HROW | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/3/2026 | Belite Bio, Inc, ADR | BLTE | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/26/2026 | Inova Technology, Inc. | INVA | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/19/2026 | NewAmsterdam Pharma Co NV | NAMS | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/19/2026 | Surrozen Inc. | SRZN | New Coverage | Overweight (N/A) |
25.09 (25.18) |
0.36% | Details | |
| 2/5/2026 | WAVE Life Sciences | WVE | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/16/2026 | Belite Bio, Inc, ADR | BLTE | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/11/2025 | CAMP4 Therapeutics Corp | CAMP | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/24/2025 | Belite Bio, Inc, ADR | BLTE | New Coverage | Overweight (N/A) |
120.56 (150.32) |
24.68% | Details | |
| 10/27/2025 | WAVE Life Sciences | WVE | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/15/2025 | Xencor, Inc. | XNCR | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/13/2025 | Tvardi Therapeutics Inc | TVRD | Downgrade | Neutral (Overweight) |
41.60 (2.52) |
-93.94% | Details | |
| 10/6/2025 | Xencor, Inc. | XNCR | New Coverage | Overweight (N/A) |
11.77 (14.51) |
23.28% | Details | |
| 10/2/2025 | CAMP4 Therapeutics Corp | CAMP | New Coverage | Overweight (N/A) |
2.95 (4.11) |
39.32% | Details | |
| 8/7/2025 | Inova Technology, Inc. | INVA | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/18/2025 | Harrow Health | HROW | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/11/2025 | WAVE Life Sciences | WVE | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/11/2025 | Harrow Health | HROW | New Coverage | Overweight (N/A) |
31.37 (43.19) |
37.68% | Details | |
| 7/11/2025 | Inova Technology, Inc. | INVA | New Coverage | Overweight (N/A) |
19.06 (23.75) |
24.61% | Details | |
| 7/11/2025 | Tvardi Therapeutics Inc | TVRD | New Coverage | Overweight (N/A) |
22.67 (41.60) |
83.5% | Details | |
| 6/23/2025 | WAVE Life Sciences | WVE | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/12/2025 | NewAmsterdam Pharma Co NV | NAMS | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/4/2025 | NewAmsterdam Pharma Co NV | NAMS | New Coverage | Overweight (N/A) |
18.69 (32.44) |
73.57% | Details | |
| 5/2/2025 | 89bio Inc. | ETNB | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/29/2025 | WAVE Life Sciences | WVE | New Coverage | Overweight (N/A) |
6.73 (6.05) |
-10.1% | Details |
